Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab and nivolumab + ipilimumab in virus-associated and virus-negative solid tumors
NL-OMON47503Phase 2Active, not recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Nov 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of nivolumab and ipilimumab in head and neck squamous cell carcinoma (HNSCC), Merkel cell carcinoma (MCC), nasopharyngeal carcinoma (NPC) and 5 more (3 cohorts), sponsored by Bristol Myers Squibb. Primary endpoints: Safety and tolerability in neoadjuvant cohort and Objective response rate in metastatic/recurrent cohort. Started Nov 2015; status: active, not recruiting.
02
Drugs
nivolumabipilimumab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)Merkel cell carcinoma (MCC)nasopharyngeal carcinoma (NPC)cervical squamous cell carcinoma (CSCC)vaginal squamous cell carcinoma (SCCV)
Beyond the preview
Go deeper on NL-OMON47503.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47503.